Table 3 Subgroup analyses for the outcome of relapse-free survival
Subgroups | No. of studies | HR (95% CI) | I2 (P value) |
|---|---|---|---|
Population | |||
Children | 3 | 3.22 (1.68–6.18) | 57.6% (0.10) |
Adult | 4 | 1.69 (1.02–2.80) | 69.5% (0.02) |
Design | |||
Prospective | 5 | 2.37 (1.12–5.01) | 77.7% (< 0.01) |
Retrospective | 5 | 2.71 (1.58–4.64) | 73.5% (< 0.01) |
Region | |||
Europe | 5 | 2.38 (1.26–4.50) | 83.5% (< 0.01) |
USA | 3 | 2.87 (1.35–6.10) | 56.7% (0.10) |
Asia | 2 | 2.61 (0.66–10.40) | 75.6% (0.04) |
Detection method | |||
PCR | 5 | 2.09 (1.07–4.08) | 75.3% (< 0.01) |
FC | 4 | 3.58 (1.73–7.40) | 73.8% (< 0.01) |
Adjustment | |||
Adjusted | 7 | 2.50 (1.64–3.82) | 64.4% (0.01) |
Crude | 3 | 2.93 (0.81–10.64) | 86.3% (< 0.01) |